High-Risk COVID-19 Patients Remdesivir Study

Eligible high-risk patients were aged at least 18 years, had ongoing COVID-19 confirmed by SARS-CoV-2 nasopharyngeal sample positivity using real-time polymerase chain reaction (RT-PCR) and antigenic testing, and possessed ≥ 1 predefined patient-level risk factor for disease progression at inclusion. Predefined patient-level risk factors were essential hypertension, obesity (body mass index > 25 kg/m²), chronic cardiovascular disease, chronic cerebrovascular disease, chronic pulmonary disease, chronic renal disease, chronic liver disease, diabetes mellitus, immunocompromised state, and active oncological and haematological malignancies. All eligible patients were included consecutively at COVID-19 diagnosis if they consented to receive remdesivir for a minimum of 3 days and promptly started after diagnosis ascertainment. No a priori exclusion criteria were used. COVID-19 severity was given according to the World Health Organisation (WHO) criteria (WHO 2022 ). After inclusion completion, the cohort was stratified into two subgroups according to active haematological malignancy as a comorbidity.